CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Azarga Brinzolamide and timolol maleate suspension Glaucoma and ocular hypertension List in a similar manner to other drugs in class Complete
Reyataz Atazanavir HIV infection List in a similar manner to other drugs in class Complete
Axert Almotriptan Migraine List in a similar manner to other drugs in class Complete
Pegasys RBV Peginterferon alfa-2a and Ribavirin Hepatitis C, chronic List in a similar manner to other drugs in class Complete
Teveten Plus Eprosartan mesylate/ hydrochlorothiazide Hypertension, Essential List in a similar manner to other drugs in class Complete
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete
Telzir Fosamprenavir calcium HIV infection List in a similar manner to other drugs in class Complete
Myfortic Mycophenolate sodium Organ rejection in allogeneic renal transplants, Prophylaxis List in a similar manner to other drugs in class Complete
Kivexa Abacavir/lamivudine HIV infection List in a similar manner to other drugs in class Complete
Pantoloc M Pantoprazole magnesium Gastric acid secretion, reduction of List in a similar manner to other drugs in class Complete
Last Updated : May 15, 2024